+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acute Lymphocytic Leukemia Therapeutics Market Size, Share & Trends Analysis Report By Product, By Chemotherapy, By Application, By Age Group, By Gender, By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 120 Pages
  • August 2024
  • Region: Global
  • Grand View Research
  • ID: 5998856
Description Jump to:

Acute Lymphocytic Leukemia Therapeutics Market Growth & Trends

The global acute lymphocytic leukemia therapeutics market size is anticipated to reach USD 4.99 billion by 2030. The market is projected to grow at a CAGR of 7.0% from 2024 to 2030. Increasing public and private initiatives for diagnosis of Acute Lymphoblastic Leukemia (ALL), rising number of bone marrow biopsies, and availability of other treatment options are factors expected to increase the adoption of ALL procedures. For instance, The Baby Friendly Initiative Program by UNICEF (UK) and SickKids-Caribbean Initiative, a collaborative approach between hospitals and healthcare institutions in Canada, aim to provide free diagnosis and treatment services to infants suffering from ALL, who meet certain eligibility criteria.

Furthermore, rising incidence of ALL is anticipated to boost the market. The disease is prevalent among children below 5 years of age. The risk of contracting ALL is the highest between the ages of 0 and 20. On the other hand, adults are also at a risk of developing this condition. The median age of men diagnosed with this condition is approximately 55 years.

Acute Lymphocytic Leukemia Therapeutics Market Report Highlights

  • Chemotherapy accounted for the largest market revenue share of 39.9% in 2023. Chemotherapy has shown success in the treatment of ALL by achieving high rates of remission and long-term survival.
  • The precursor B-cell acute lymphocytic leukemia segment accounted for the market share of 40.4% in 2023. The incidence of precursor B-cell ALL has been increasing in recent years due to several factors such as improvements in diagnostic techniques, which have led to better identification of the disease.
  • The children (0-18) segment accounted for the market share of 63.9% in 2023. Acute lymphocytic leukemia is the most common type of cancer in children, accounting for about 25% of all childhood cancers.
  • The male segment accounted for the market share of 57.1% in 2023 and the female segment is expected to register a CAGR of 6.7% during the forecast period.
  • North America acute lymphocytic leukemia therapeutics held a dominant position with a share of 37.6% in 2023. The U.S. acute lymphocytic leukemia therapeutics dominated the North America market with a share of 89.3% in 2023.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Acute Lymphocytic Leukemia Therapeutics Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Acute Lymphocytic Leukemia Therapeutics Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Acute Lymphocytic Leukemia Therapeutics Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Acute Lymphocytic Leukemia Therapeutics Market: Product Movement Analysis, 2023 & 2030 (USD Million)
4.3. Chemotherapy
4.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.1. Hyper-CVAD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.2. CALGB 8811 Regimen Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.3. Linker Regimen Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.4. Nucleoside Metabolic Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.5. Oncaspar Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Targeted Therapy
4.4.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Radiation Therapy
4.5.1. Radiation Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Stem Cell Transplantation
4.6.1. Stem Cell Transplantation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Acute Lymphocytic Leukemia Therapeutics Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Acute Lymphocytic Leukemia Therapeutics Market: Application Movement Analysis, 2023 & 2030 (USD Million)
5.3. Philadelphia Chromosome
5.3.1. Philadelphia Chromosome Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Precursor B-cell ALL
5.4.1. Precursor B-cell ALL Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. T-cell ALL
5.5.1. T-cell ALL Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Acute Lymphocytic Leukemia Therapeutics Market: Age Group Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Acute Lymphocytic Leukemia Therapeutics Market: Age Group Movement Analysis, 2023 & 2030 (USD Million)
6.3. Children (0-18)
6.3.1. Children (0-18) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Adults (19 +)
6.4.1. Adults (19 +) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Acute Lymphocytic Leukemia Therapeutics Market: Gender Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Acute Lymphocytic Leukemia Therapeutics Market: Gender Movement Analysis, 2023 & 2030 (USD Million)
7.3. Male
7.3.1. Male Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Female
7.4.1. Female Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Acute Lymphocytic Leukemia Therapeutics Market: End Use Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Acute Lymphocytic Leukemia Therapeutics Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
8.3. Hospitals & Clinics
8.3.1. Hospitals & clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Cancer Care Centers
8.4.1. Cancer Care Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Research and academic institutes
8.5.1. Research and Academic Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Acute Lymphocytic Leukemia Therapeutics Market: Regional Estimates & Trend Analysis
9.1. Acute Lymphocytic Leukemia Therapeutics Market Share, By Region, 2023 & 2030, USD Million
9.2. North America
9.2.1. North America Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.2.2. U.S.
9.2.2.1. U.S. Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.2.3. Canada
9.2.3.1. Canada Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.2.4. Mexico
9.2.4.1. Mexico Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3. Europe
9.3.1. Europe Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.2. UK
9.3.2.1. UK Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.3. Germany
9.3.3.1. Germany Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.4. France
9.3.4.1. France Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.5. Italy
9.3.5.1. Italy Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.6. Spain
9.3.6.1. Spain Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.7. Denmark
9.3.7.1. Denmark Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.8. Sweden
9.3.8.1. Sweden Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.9. Norway
9.3.9.1. Norway Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4. Asia Pacific
9.4.1. Asia Pacific Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.2. China
9.4.2.1. China Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.3. Japan
9.4.3.1. Japan Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.4. India
9.4.4.1. India Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.5. South Korea
9.4.5.1. South Korea Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.6. Australia
9.4.6.1. Australia Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.7. Thailand
9.4.7.1. Thailand Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5. Latin America
9.5.1. Latin America Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.2. Brazil
9.5.2.1. Brazil Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.3. Argentina
9.5.3.1. Argentina Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6. Middle East and Africa
9.6.1. Middle East and Africa Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.2. South Africa
9.6.2.1. South Africa Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.3. Saudi Arabia
9.6.3.1. Saudi Arabia Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.4. UAE
9.6.4.1. UAE Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.5. Kuwait
9.6.5.1. Kuwait Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis by Key Market Participants
10.2. Company Categorization
10.3. Company Heat Map Analysis
10.4. Company Profiles
10.4.1. Bristol-Myer Squibb Company
10.4.1.1. Participant’s Overview
10.4.1.2. Financial Performance
10.4.1.3. Product Benchmarking
10.4.1.4. Recent Developments/ Strategic Initiatives
10.4.2. Celegene Corporation
10.4.2.1. Participant’s Overview
10.4.2.2. Financial Performance
10.4.2.3. Product Benchmarking
10.4.2.4. Recent Developments/ Strategic Initiatives
10.4.3. Eisai Co., Ltd.
10.4.3.1. Participant’s Overview
10.4.3.2. Financial Performance
10.4.3.3. Product Benchmarking
10.4.3.4. Recent Developments/ Strategic Initiatives
10.4.4. Erytech Pharma
10.4.4.1. Participant’s Overview
10.4.4.2. Financial Performance
10.4.4.3. Product Benchmarking
10.4.4.4. Recent Developments/ Strategic Initiatives
10.4.5. F. Hoffmann-La Roche Ltd
10.4.5.1. Participant’s Overview
10.4.5.2. Financial Performance
10.4.5.3. Product Benchmarking
10.4.5.4. Recent Developments/ Strategic Initiatives
10.4.6. Genmab A/S
10.4.6.1. Participant’s Overview
10.4.6.2. Financial Performance
10.4.6.3. Product Benchmarking
10.4.6.4. Recent Developments/ Strategic Initiatives
10.4.7. GSK plc.
10.4.7.1. Participant’s Overview
10.4.7.2. Financial Performance
10.4.7.3. Product Benchmarking
10.4.7.4. Recent Developments/ Strategic Initiatives
10.4.8. Novartis AG
10.4.8.1. Participant’s Overview
10.4.8.2. Financial Performance
10.4.8.3. Product Benchmarking
10.4.8.4. Recent Developments/ Strategic Initiatives
10.4.9. Pfizer Inc.
10.4.9.1. Participant’s Overview
10.4.9.2. Financial Performance
10.4.9.3. Product Benchmarking
10.4.9.4. Recent Developments/ Strategic Initiatives
10.4.10. Sanofi
10.4.10.1. Participant’s Overview
10.4.10.2. Financial Performance
10.4.10.3. Product Benchmarking
10.4.10.4. Recent Developments/ Strategic Initiatives

Companies Mentioned

  • Bristol-Myer Squibb Company
  • Celegene Corporation
  • Eisai Co., Ltd.
  • Erytech Pharma
  • F. Hoffmann-La Roche Ltd
  • Genmab A/S
  • GSK plc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedAugust 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 3.12 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.99 Billion
Compound Annual Growth Rate7.0%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Acute Lymphocytic Leukemia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Acute Lymphocytic Leukemia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 187 Pages
  • Global
From
Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Global Market Report 2024 - Product Image

Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Acute Lymphocytic Leukemia (ALL) - Pipeline Insight, 2024 - Product Image

Acute Lymphocytic Leukemia (ALL) - Pipeline Insight, 2024

  • Clinical Trials
  • 240 Pages
  • Global
From
Acute Lymphocytic Leukemia (ALL) - Market Insight, Epidemiology and Market Forecast - 2032 - Product Image

Acute Lymphocytic Leukemia (ALL) - Market Insight, Epidemiology and Market Forecast - 2032

  • Report
  • 257 Pages
  • Global
From
Leukemia Therapeutics Market Analysis & Forecast to 2024-2034 - Product Image

Leukemia Therapeutics Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From

About the Acute Lymphocytic Leukemia Drugs Market

Acute Lymphocytic Leukemia (ALL) Drugs are a type of medication used to treat the cancerous condition of ALL. These drugs are used to reduce the number of cancerous cells in the body, and to prevent the spread of the disease. Commonly used ALL drugs include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy is the most common form of treatment, and involves the use of drugs to kill cancer cells. Targeted therapy is a newer form of treatment that uses drugs to target specific cancer cells, while immunotherapy uses the body’s own immune system to fight the cancer. The Acute Lymphocytic Leukemia Drugs market is a rapidly growing sector, with many companies developing new treatments and therapies. Some of the major players in the market include Novartis, Pfizer, Celgene, and Bristol-Myers Squibb. Other companies such as Merck, Amgen, and Gilead Sciences are also active in the market. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.